SCHEMBL3471394

SCHEMBL3471394

O=C(O)CCCP(=O)(O)OS

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
TSHR P16473 3/20 0.42
NFKB1 P19838 1/20 0.42
PMP22 Q01453 1/20 0.42
FOLH1 Q04609 2/20 0.41
ALDH1A1 P00352 1/20 0.40
CAMK2A Q9UQM7 1/20 0.39
NPSR1 Q6W5P4 2/20 0.37
GABRR3 A8MPY1 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
HDAC3 O15379 1/20 0.37
GABBR2 O75899 1/20 0.37
CYP1A2 P05177 1/20 0.37
THRB P10828 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRR1 P24046 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473015 0.91 TSHR (0.50) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL5060575 0.88 GRM8 (0.38) LMNASLC22A6TSHRFOLH1BLM
SCHEMBL12473687 0.77 LMNA (0.43) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL234493 0.77 LMNA (0.43) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL4453714 0.77 ALDH1A1 (0.50) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL28252207 0.76 CAMK2A (0.42) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL307497 0.75 TYMS (0.58) LMNASLC22A6TSHRNFKB1PMP22
SCHEMBL1487740 0.74 PPARD (0.57) SLC22A6TSHRALDH1A1KMT2AHDAC11
SCHEMBL29589 0.73
SCHEMBL11196604 0.73 TYMS (0.55) LMNASLC22A6TSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125029-B1 CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS LIPOCALYX GMBH (DE) 2016-10-12 EP disclosed
US-20130011916-A1 CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS LIPOCALYX GMBH (DE) 2013-01-10 US disclosed
US-20100022621-A1 CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS MDRNA RESEARCH, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022621-A1 CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS TEAD4, CREB1, ELF3 LMNA 315/4885SLC22A6 129/4885TSHR 538/4885
US-20130011916-A1 CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS TEAD4, CREB1, ELF3 LMNA 315/4885SLC22A6 129/4885TSHR 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.